Skip to main content


Log in

Monoaminergic system and depression

  • Review
  • Published:
Cell and Tissue Research Aims and scope Submit manuscript


Major depressive disorder is a severe, disabling disorder that affects around 4.7% of the population worldwide. Based on the monoaminergic hypothesis of depression, monoamine reuptake inhibitors have been developed as antidepressants and nowadays, they are used widely in clinical practice. However, these drugs have a limited efficacy and a slow onset of therapeutic action. Several strategies have been implemented to overcome these limitations, including switching to other drugs or introducing combined or augmentation therapies. In clinical practice, the most often used augmenting drugs are lithium, triiodothyronine, atypical antipsychotics, buspirone, and pindolol, although some others are in the pipeline. Moreover, multitarget antidepressants have been developed to improve efficacy. Despite the enormous effort exerted to improve these monoaminergic drugs, they still fail to produce a rapid and sustained antidepressant response in a substantial proportion of depressed patients. Recently, new compounds that target other neurotransmission system, such as the glutamatergic system, have become the focus of research into fast-acting antidepressant agents. These promising alternatives could represent a new pharmacological trend in the management of depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others


  • Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC (2001) Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 158:1617–1622

    Article  CAS  PubMed  Google Scholar 

  • American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5). American Psychiatric Publishing, Arlington

    Book  Google Scholar 

  • Aronson R, Offman HJ, Joffe RT, Naylor CD (1996) Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53:842–848

    Article  CAS  PubMed  Google Scholar 

  • Artigas F, Romero L, de Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378–383

    Article  CAS  PubMed  Google Scholar 

  • Artigas F, Bortolozzi A, Celada P (2018) Can we increase speed and efficacy of antidepressant treatments? Part I: general aspects and monoamine-based strategies. Eur Neuropsychopharmacol 28:445–456

    Article  CAS  PubMed  Google Scholar 

  • Ballesteros J, Callado LF (2004) Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 79:137–147

    Article  CAS  PubMed  Google Scholar 

  • Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M (2014) Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 28:331–342

    Article  CAS  PubMed  Google Scholar 

  • Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA (2009) Opiates as antidepressants. Curr Pharm Des 15:1612–1622

    Article  CAS  PubMed  Google Scholar 

  • Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220–226

    Article  CAS  PubMed  Google Scholar 

  • Boothman LJ, Mitchell SN, Sharp T (2006) Investigation of the SSRI augmentation properties of 5-HT(2) receptor antagonists using in vivo microdialysis. Neuropharmacology 50:726–732

    Article  CAS  PubMed  Google Scholar 

  • Carvalho AF, Berk M, Hyphantis TN, McIntyre RS (2014) The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 83:70–88

    Article  PubMed  Google Scholar 

  • Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29:252–265

    PubMed  PubMed Central  Google Scholar 

  • Coppen A, Shaw DM, Herzberg B, Maggs R (1967) Tryptophan in the treatment of depression. Lancet 2:1178–1180

    Article  CAS  PubMed  Google Scholar 

  • de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9:628–642

    Article  CAS  PubMed  Google Scholar 

  • Domenjoz R, Theobald W (1959) On the pharmacology of tofranil N-(3-dimethylaminopropyl)-iminodibenzyl hydrochloride. Arch Int Pharmacodyn Ther 120:450–489

    CAS  PubMed  Google Scholar 

  • Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, Vos T, Whiteford HA (2013a) Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 10:e1001547

    Article  PubMed  PubMed Central  Google Scholar 

  • Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, Whiteford HA (2013b) Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 43:471–481

    Article  CAS  PubMed  Google Scholar 

  • GBD Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602

    Article  Google Scholar 

  • Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU (2013) Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 13:851–870

    Article  CAS  PubMed  Google Scholar 

  • Insel TR, Wang PS (2009) The STAR*D trial: revealing the need for better treatments. Psychiatr Serv 60:1466–1467

    Article  PubMed  Google Scholar 

  • Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894–902

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kuhn R (1957) Treatment of depressive states with an iminodibenzyl derivative (G 22355). Schweiz Med Wochenschr 87:1135–1140

    CAS  PubMed  Google Scholar 

  • Lane RM (2015) Antidepressant drug development: focus on triple monoamine reuptake inhibition. J Psychopharmacol 29:526–544

    Article  CAS  PubMed  Google Scholar 

  • Lemieux G, Davignon A, Genest J (1956) Depressive states during Rauwolfia therapy for arterial hypertension; a report of 30 cases. Can Med Assoc J 74:522–526

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lifschytz T, Segman R, Shalom G, Lerer B, Gur E, Golzer T, Newman ME (2006) Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 7:203–210

    Article  CAS  PubMed  Google Scholar 

  • Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC (2018) Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep 8:2861

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Loomer HP, Saunders JC, Kline NS (1957) A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc 8:129–141

    CAS  PubMed  Google Scholar 

  • Lopez-Munoz F, Alamo C (2009) Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 15:1563–1586

    Article  CAS  PubMed  Google Scholar 

  • McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, Kennedy SH, Rong C, Jerrell JM (2017) The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis. J Clin Psychopharmacol 37:412–418

    Article  CAS  PubMed  Google Scholar 

  • Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sanchez E, Gutierrez-Rojas L, Meana JJ (2018) Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs

  • Montoya A, Bruins R, Katzman MA, Blier P (2016) The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat 12:541–557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moreira R (2011) The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 31(Suppl 1):5–17

    Article  CAS  PubMed  Google Scholar 

  • National Institute for Clinical Excellence (2004) Depression: management of depression in primary and secondary care (National Clinical Practice Guideline No 23). NICE, London

    Google Scholar 

  • Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980–991

    Article  PubMed  Google Scholar 

  • Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519–1530

    Article  PubMed  Google Scholar 

  • Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F (1997) Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:1594–1597

    Article  CAS  PubMed  Google Scholar 

  • Perez-Caballero L, Perez-Egea R, Romero-Grimaldi C, Puigdemont D, Molet J, Caso JR, Mico JA, Perez V, Leza JC, Berrocoso E (2014) Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. Mol Psychiatry 19:607–614

    Article  CAS  PubMed  Google Scholar 

  • Posternak MA, Zimmerman M (2005) Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 66:148–158

    Article  CAS  PubMed  Google Scholar 

  • Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917

    Article  PubMed  Google Scholar 

  • Sahli ZT, Banerjee P, Tarazi FI (2016) The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discovery 11:515–523

    Article  CAS  Google Scholar 

  • Sanchez C, Asin KE, Artigas F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 145:43–57

    Article  CAS  PubMed  Google Scholar 

  • Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509–522

    Article  CAS  PubMed  Google Scholar 

  • Smith K (2014) Mental health: a world of depression. Nature 515:181

    PubMed  Google Scholar 

  • Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234–241

    Article  CAS  PubMed  Google Scholar 

  • Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH (2010) Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 25:189–198

    Article  PubMed  Google Scholar 

  • Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ, Team SDS (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252

    Article  CAS  PubMed  Google Scholar 

  • UK ECT Review Group (2003) Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361:799–808

    Article  Google Scholar 

  • Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry:appiajp201818020138

  • Won E, Kim YK (2017) An oldie but goodie: lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms. Int J Mol Sci 18

  • World Health Organization (2001) The world health report 2001: mental health: now understanding, new hope. World Health Organization, Geneva

    Google Scholar 

  • World Health Organization (2016) Out of the shadows: making mental health a global development priority. World Health Organization, Washington

    Google Scholar 

  • World Health Organization (2017) Depression and other common mental disorders: global health estimates. World Health Organization, Geneva

    Google Scholar 

Download references


This work was supported by grants from the “Ministerio de Economía y Competitividad” (MINECO), co-financed by “Fondo Europeo de Desarrollo Regional” FEDER “A way to build Europe” (SAF2015-68647-R; “Instituto de Salud Carlos III (PI12/00915, PI18/01691)); the “Centro de Investigación Biomédica en Red de Salud Mental-CIBERSAM” (Spain; CB/07/09/0033); the “Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía” (Spain; CTS-510 and CTS-7748); the “Consejería de Salud de la Junta de Andalucía” (Spain; PI-0134-2018); the “Fundación Progreso y Salud de la Junta de Andalucía” (PI-0080-2017); and a 2015 NARSAD Young Investigator Grant from the Brain Behavior Research Foundation (NARSAD 23982).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Esther Berrocoso.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perez-Caballero, L., Torres-Sanchez, S., Romero-López-Alberca, C. et al. Monoaminergic system and depression. Cell Tissue Res 377, 107–113 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: